- Location
AbbVie
"-
An Economic Option and Preferred by The Healthcare or Pharmaceutical Industry
Jan 14, 2015Reusable passive packaging is an economic option and is preferred by the healthcare or pharmaceutical industry, according to a survey conducted by global provider of temperature assurance packaging Sonoco ThermoSafe. The 2014 survey was ...
Tags: package efficiency, ownership costs, pricing, Agriculture
-
Initiation of Secure Supply Chain Pilot Program to Enhance The Security of Imported Drugs
Feb 19, 2014The U.S. Food and Drug Administration is announcing the initiation of the Secure Supply Chain Pilot Program to enhance the security of imported drugs. In August 2013, the FDA published a notice in the Federal Register (78 FR 51192) to ...
-
Monoclonal Antibody Agents Have Been Successfully Used in The Treatment of Tumors
Dec 23, 2013Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents ...
-
AbbVie's Humira Was Rejected by The US FDA Advisors for Use in The Treatment
Jul 25, 2013AbbVie's Humira (adalimumab), a rheumatoid arthritis drug, has been rejected by the US FDA advisors for use in the treatment of a spinal inflammatory disease, non-radiographic axial spondyloarthritis. The FDA's Arthritis Advisory ...
-
AbbVie Has Announced The Availability of New,Higher-Dose of Creon Delayed-Release Capsules
May 31, 2013Research-based biopharmaceutical company AbbVie has announced the availability of new, higher-dose of Creon (pancrelipase) delayed-release capsules in the US. Indicated for patients with exocrine pancreatic insufficiency (EPI), 36,000 ...
-
Mylan Pharmaceuticals Has Introduced Fenofibrate Tablets, 48 Mg and 145 Mg
May 22, 2013Mylan Pharmaceuticals, the subsidiary of Mylan, has introduced Fenofibrate tablets, 48 mg and 145 mg. The company has received the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application ...
Tags: Mylan, Generic Version
-
Galapagos and Abbvie Have Extended Their GLPG0634 Clinical Development Collaboration
May 20, 2013Galapagos and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. As per the extension agreement, Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to ...
Tags: AbbVie, Galapagos, Crohn's Disease
-
Zogenix, Battelle Deep Their Cooperation for Dosepro Drug Delivery System
Apr 2, 2013US-based pharmaceutical company Zogenix has extended its co-marketing partnership with Battelle, for the DosePro needle-free drug delivery system through 29 March 2014. The partnership is focused on advancing out-licensing opportunities ...
-
Pfizer Has Decided to Discontinue The Development of Filibuvir
Mar 13, 2013Biopharmaceutical company Pfizer has decided to discontinue the development of filibuvir, an experimental hepatitis C drug, following a strategic review and capital allocation. The drug, which is in mid-stage clinical testing, is facing ...
Tags: Pfizer, filibuvir drug, drug
-
Abbott's Latest Cardiac Diagnostics Product Represents a Growth Over Next Few Years
Feb 18, 2013January was a month of change for healthcare giant Abbott said a senior medical devices analyst from GlobalData who asserted that the company’s latest cardiac diagnostics product represents a pathway to growth over the next few years. ...
Tags: Abbott, Diagnostics, medical devices analyst
